For more information or to register for this event, visit Why Caregiver Experience Belongs in Evidence Generation.

The rapidly expanding landscape of biosimilars presents significant opportunities for increasing patient access to cost-effective alternatives to brand-name biologics, but this also creates unique ...

In the current drug development landscape, data serves as the engine that drives faster and more strategic decisions. Despite the availability of data in preclinical research, organizations continue ...

The clinical success of CRISPR-based treatments is fundamentally dependent on sophisticated gRNA targeting systems that ...